Insider Selling: Accolade, Inc. (NASDAQ:ACCD) EVP Sells $12,891.60 in Stock

Accolade, Inc. (NASDAQ:ACCD) EVP Richard Eskew sold 3,581 shares of the firm’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $3.60, for a total transaction of $12,891.60. Following the completion of the transaction, the executive vice president now owns 62,507 shares of the company’s stock, valued at approximately $225,025.20. The trade was a 5.42 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Richard Eskew also recently made the following trade(s):

• On Monday, November 4th, Richard Eskew sold 336 shares of Accolade stock. The shares were sold at an average price of $3.15, for a total transaction of $1,058.40.
• On Wednesday, October 2nd, Richard Eskew sold 334 shares of Accolade stock. The shares were sold at an average price of $3.70, for a total value of $1,235.80.

Accolade Price Performance

Shares of NASDAQ:ACCD opened at $3.69 on Friday. The stock has a market cap of $297.18 million, a P/E ratio of -3.58 and a beta of 2.07. Accolade, Inc. has a 12 month low of $3.08 and a 12 month high of $15.36. The company has a 50 day moving average of $3.59 and a 200 day moving average of $4.34. The company has a current ratio of 2.72, a quick ratio of 2.72 and a debt-to-equity ratio of 0.49.

Accolade (NASDAQ:ACCD) last issued its earnings results on Tuesday, October 8th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.14. Accolade had a negative return on equity of 18.43% and a negative net margin of 18.16%. The business had revenue of $106.40 million during the quarter, compared to analyst estimates of $104.87 million. During the same quarter in the prior year, the firm earned ($0.43) earnings per share. Accolade’s revenue for the quarter was up 9.8% on a year-over-year basis. As a group, sell-side analysts forecast that Accolade, Inc. will post -0.92 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently commented on ACCD. Wells Fargo & Company cut their target price on Accolade from $7.00 to $6.00 and set an “equal weight” rating for the company in a research report on Friday, October 11th. Stephens lowered their target price on Accolade from $10.00 to $8.00 and set an “overweight” rating for the company in a research note on Wednesday, October 9th. Canaccord Genuity Group dropped their target price on shares of Accolade from $13.00 to $7.00 and set a “buy” rating for the company in a research report on Wednesday, October 9th. Needham & Company LLC restated a “buy” rating and set a $8.00 price objective on shares of Accolade in a report on Monday, October 7th. Finally, Truist Financial cut their price objective on Accolade from $9.00 to $7.50 and set a “buy” rating on the stock in a report on Wednesday, October 9th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $9.04.

Institutional Trading of Accolade

Several institutional investors and hedge funds have recently bought and sold shares of ACCD. Mission Creek Capital Partners Inc. purchased a new stake in shares of Accolade in the third quarter worth $38,000. SG Americas Securities LLC bought a new position in Accolade in the 2nd quarter valued at approximately $43,000. IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new stake in Accolade during the 3rd quarter valued at $46,000. Wolverine Trading LLC bought a new stake in shares of Accolade in the 3rd quarter worth $51,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Accolade by 22.8% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,373 shares of the company’s stock worth $73,000 after purchasing an additional 3,789 shares during the last quarter. 84.99% of the stock is currently owned by hedge funds and other institutional investors.

Accolade Company Profile

Accolade, Inc, together with its subsidiaries, engages in the development and provision of personalized and technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based intelligent technology and multimodal support from a team of advocates and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, women’s health specialists, case management specialists, expert medical opinion providers, and primary care physicians.